富马酸伏诺拉生(Vonoprazan Fumarate) - 药物靶点：H+/K+ ATPase_在研适应症：非糜烂性胃食管反流病，糜烂性食管炎，胃灼热_专利_临床

概要

基本信息

药物类型

小分子化药

别名

VONOPION、Vonoprazan、Vonoprazan fumarate (JAN/USAN)

+ [14]

靶点

H+/K+ ATPase

作用方式

阻滞剂

作用机制

H+/K+ ATPase阻滞剂(钾离子转运ATP酶复合体阻滞剂)

治疗领域

感染消化系统疾病口颌疾病+ [4]

在研适应症

非糜烂性胃食管反流病糜烂性食管炎胃灼热+ [10]

非在研适应症

非糜烂性反流病

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Takeda Pharmaceutical Co., Ltd.

广州绿十字制药股份有限公司Takeda Pharmaceuticals Korea Co., Ltd.

+ [4]

非在研机构

Hanlim Pharm Co., Ltd.

权益机构

Takeda Pharmaceutical Co., Ltd.

Phathom Pharmaceuticals, Inc.

Lupin Ltd

+ [3]

最高研发阶段批准上市

首次获批日期

日本 (2014-12-26),

十二指肠溃疡反流性食管炎幽门螺杆菌感染+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C21H20FN3O6S

InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N

CAS号881681-01-2

关联

505

项与富马酸伏诺拉生相关的临床试验

NCT07439445

/ Not yet recruitingN/AIIT

Efficacy and Safety of Simplified Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line Helicobacter Pylori Eradication

To investigate the efficacy, safety, and compliance of a simplified strategy using vonoprazan plus clarithromycin for first-line treatment in patients with Helicobacter pylori infection, among those infected with strains without clarithromycin resistance gene mutations based on fecal clarithromycin resistance gene detection.

开始日期2026-02-24

申办/合作机构

北京大学第一医院

NCT07293910

/ Recruiting临床2期IIT

Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity. Its clinical significance is profound: it is classified as a Group 1 carcinogen by the World Health Organization and is a primary cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. The current first-line treatment, a PPI-based triple therapy (PPI + clarithromycin + amoxicillin), is experiencing a decline in efficacy (cure rates of 50-70%) due to widespread antibiotic resistance and compliance issues. To overcome this, newer agents like Vonoprazan Fumarate, a Potassium-Competitive Acid Blocker (P-CAB), are being adopted. Vonoprazan works by reversibly inhibiting the H+, K+ ATPase pump achieving stronger and longer-lasting acid suppression than PPIs because it does not require acid activation and is more stable in an acidic environment. In addition to pharmacological treatment, adjunctive therapies show promise. Vitamin D, acting through Vitamin D Receptor (VDR), assists in eradication by upregulating antimicrobial proteins like beta-defensin and cathelicidin, and its metabolite can cause bacterial cell lysis. Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth, inhibiting adhesion, and exerting an anti-inflammatory effect through decreased interleukin-8 production. Finally, helicobacter pylori infection is marked by significant inflammation and oxidative stress. The bacterial protein TIP alpha induces high levels of the pro-inflammatory cytokine TNF alpha. Furthermore, the infection increases free radical production, leading to oxidative stress reflected by high levels of malondialdehyde. Systemic inflammation is also evident as helicobacter pylori infection is associated with significantly elevated serum C-reactive protein levels, which decrease upon successful eradication.
Aim of the work:
This study aims at evaluating the safety and efficacy of Vonoprazan vs Proton Pump Inhibitor with Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection.

开始日期2026-02-15

申办/合作机构

Tanta University

NCT07352098

/ Not yet recruitingN/AIIT

Efficacy and Safety of Short-Term, High-Dose Vonoprazan-Based Dual Therapy Versus Standard-Dose Vonoprazan-Based Dual Therapy for Helicobacter Pylori Eradication: A Multicenter, Open-Label, Randomized Controlled Trial

Helicobacter pylori infection is a prevalent global gastrointestinal condition linked to chronic gastritis, peptic ulcer disease, and gastric cancer. Potent and sustained acid suppression improves eradication efficacy. Vonoprazan, a potassium-competitive acid blocker, provides rapid and stable acid inhibition and has become an important component of dual therapy with amoxicillin. However, the optimal dosing strategy and treatment duration for vonoprazan-based dual therapy are not yet fully established.
This multicenter, open-label, randomized controlled trial compares the efficacy and safety of a short-term, high-dose vonoprazan-based dual therapy (20 mg three times daily for 7 days) with a standard-dose regimen (20 mg twice daily for 14 days), both combined with amoxicillin, for first-line H. pylori eradication. Adult participants with confirmed H. pylori infection will be randomized 1:1 to the two treatment groups. The primary outcome is the eradication rate of H. pylori at 6 weeks after completion of therapy. Secondary outcomes include safety assessments and medication adherence. This study will provide evidence on whether a higher dose and shorter treatment course can achieve similar eradication rates with acceptable safety and tolerability compared to the standard regimen.

开始日期2026-02-01

申办/合作机构

山东大学齐鲁医院

[+5]

100 项与富马酸伏诺拉生相关的临床结果

登录后查看更多信息

100 项与富马酸伏诺拉生相关的转化医学

登录后查看更多信息

100 项与富马酸伏诺拉生相关的专利（医药）

登录后查看更多信息

776

项与富马酸伏诺拉生相关的文献（医药）

2026-05-01·LIFE SCIENCES

Vonoprazan mitigates diethyl nitrosamine-induced acute liver injury in mice via modulating p-AMPK/ SIRT1/ PGC-1α and Keap1/Nrf2/HO-1 pathways

Article

作者: Al-Rasheedi, Zaid F ; El-Kashef, Dalia H ; Nour, Omnia A

BACKGROUND:

Vonoprazan (VON), a potassium-competitive acid blocker, is used in the treatment of acid-related disorders including GERD, gastritis, and esophagitis besides H. pylori infection.

AIM:

This study was carried out to elucidate the hepatoprotective effect of VON against diethylnitrosamine (DN)-induced acute liver injury (ALI) in mice.

METHOD:

Thirty-six male mice were randomly alienated into six groups, including control group, VON20 group, DN-induced ALI group, VON5 + DN group, VON10 + DN group and VON20 + DN group. ALI was induced in mice using DN (150 mg/kg, i.p.). VON was orally administered at three doses (5, 10 and 20 mg/kg) for 7 days before DN injection, and DN was injected on day 7.

RESULTS:

In comparison to DN group, VON exerted hepatoprotective effect, evidenced by significant decrease in serum levels of ALT, AST, GGT and LDH. Additionally, VON administration restored oxidant/anti-oxidant balance, as presented by significant decrease in hepatic levels of MDA in addition to profound increase in hepatic level of GSH and TAC. Furthermore, VON administration attenuated DN-induced reduction in hepatic levels of p-AMPK, SIRT1, PGC-1α, Nrf2 and HO-1. VON also induced significant reduction in hepatic levels of Keap1, NF-κB and TNF-α when compared to DN. Histopathologically, VON mitigated DN-induced histopathological irregularities in hepatic tissues.

CONCLUSION:

VON suggests hepatoprotective potential, in a dose dependent manner, possibly due to their antioxidant and anti-inflammatory properties.

2026-04-01·DEN open

A Case of Gastric Neuroendocrine Tumor With a Raspberry‐Like Appearance on the Background of Acid‐Suppressive Therapy‐Related Gastropathy

Article

作者: Arakawa, Takeo ; Noma, Eriko ; Goto, Osamu ; Funabiki, Toshihiro ; Moriguchi, Yoshiaki ; Iseki, Mari ; Oka, Yasuhiro ; Nakahodo, Jun ; Iizuka, Toshiro ; Horiguchi, Shin‐ichiro

ABSTRACT:

We report the case of a 52‐year old man who was referred to our institution after a routine health check identified an asymptomatic gastric polyp. The medical history of the patient included reflux esophagitis, for which he had been treated with vonoprazan 10 mg daily for 6 years after initially receiving proton pump inhibitors. Endoscopy revealed a 4‐mm, hemispherical, uniformly reddish Yamada type II lesion on the anterior wall of the gastric body, arising from nonatrophic mucosa with multiple small hyperplastic polyps. Magnifying narrow‐band imaging revealed a regular microvascular and microsurface pattern, producing a raspberry‐like appearance. Histological examination of the biopsy specimen revealed a grade 1 neuroendocrine tumor. Contrast‐enhanced computed tomography revealed no evidence of metastatic lesions. En bloc resection was successfully performed using endoscopic submucosal dissection. Pathological examination confirmed a 5‐mm grade 1 neuroendocrine tumor with negative margins and no vascular invasion. Gastric neuroendocrine tumors with raspberry‐like morphology are rare. This case underscores the importance of considering gastric neuroendocrine tumors in the differential diagnosis of raspberry‐like gastric lesions, particularly in patients with potent acid‐suppressive therapy–related gastropathy.Trial Registration : N/A.

2026-03-01·Lancet Regional Health-Western Pacific

Vonoprazan-amoxicillin dual, rifabutin-based triple, and bismuth quadruple therapies for Helicobacter pylori rescue treatment: a multicentre, open-label, non-inferiority randomised trial

Article

作者: Lu, Hong ; Han, Yue-Hua ; Liang, Xiao ; Xu, Ping ; Wang, Jing ; Guo, Yi-Xian ; Huang, Yu ; Gao, Ya-Nan ; Li, Mei-Xuan ; Qiu, Shu-Han ; Chen, Jin-Nan

Background:

Whether vonoprazan-amoxicillin dual therapy (VA) or rifabutin-based triple study (VRA) can replace bismuth quadruple therapy (BQT) for Helicobacter pylori rescue treatment remains unclear. We aimed to evaluate the efficacy and safety of 10-day VA and VRA regimens, compared with BQT, for rescue therapy.

Methods:

We conducted an open-label, non-inferiority randomised controlled trial at three hospitals in China. Refractory H. pylori-infected patients with at least two previous treatment failures were randomly assigned (1:1:1; block sizes six) to 10 days vonoprazan-containing (20 mg twice daily) regimens of VA (amoxicillin 1000 mg three times daily); VRA (amoxicillin 1000 mg three times daily, and rifabutin 150 mg twice daily); or BQT (bismuth 110 mg, tetracycline 500 mg, and metronidazole 400 mg, all four times daily). The primary endpoint was H. pylori eradication rate evaluated by ¹³C-urea breath test. Adverse events were assessed in all patients. Non-inferiority margin was -10%. This trial is registered at ClinicalTrials.gov (NCT05874544).

Findings:

Between May 16, 2023, and Jan 31, 2025, 360 subjects (110 [31%] male and 250 [69%] female; mean age 48.4 years [SD 12.1]) were randomly assigned to VA, VRA or BQT (n = 120 per group). Intention-to-treat eradication rates were 75.8% (91/120; 95% CI 67.0-83.0) with VA, 90.0% (108/120; 95% CI 82.8-94.5) with VRA, and 90.8% (109/120; 95% CI 83.8-95.1) with BQT. Non-inferiority of VA to BQT was not established (difference -15.0%; 95% CI -24.2 to -5.8; p = 0.86), whereas VRA was non-inferior to BQT (difference -0.8%; 95% CI -8.3 to 6.6; p = 0.0078). Resistance rates for amoxicillin, rifabutin, tetracycline, and metronidazole were 10%, <1%, 0.0%, and 96%, respectively. Amoxicillin resistance, BMI ≥25 kg/m², and smoking reduced efficacy in the VA group only (p < 0.0001, p = 0.023, and p = 0.011, respectively). Adverse events occurred in 8% (10) of VA, 25% (30) of VRA, and 53% (64) of BQT; fever (10 [8%]) and neutropenia (16 [13%]) were more frequent with VRA.

Interpretation:

Ten-day VRA therapy is a viable alternative to BQT therapy for H. pylori rescue treatment with fewer adverse events, whereas VA therapy showed unacceptable efficacy.

Funding:

National Natural Science Foundation of China, and Xinyi Digestive Disease Fund Project, College of Digestive Sciences, Shanghai Jiao Tong University School of Medicine.

561

项与富马酸伏诺拉生相关的新闻（医药）

2026-04-07

·医药经济报

三重机制，胃康无幽 | 荆花胃康胶丸联合二联方案为Hp治疗提供高质量新选择

张蕊河北医科大学第一医院，胃肠病诊疗中心河北省研究型医院学会消化专委会委员河北省中医药学会消化整合专委会委员河北中西医结合肠道健康委员会委员作为消化科医生，您一定遇到过这样的患者：幽门螺杆菌（Hp）阳性慢性胃炎，需要根除治疗。但患者一听要服用三四种药，还要加上铋剂，便流露出抵触情绪：“我胃本来就不好，吃这么多药能受得了吗？”尤其是老年患者、肝肾功能不全者，或曾有过药物不良反应经历的人，对铋剂四联疗法更是心存顾虑。可问题是——不用铋剂，根除率还能保证吗？有没有一种方案，既能减少药物负担，又能降低复发风险，还能真正改善患者的长期预后？ 1 标准疗法的边界疗效之外，还有哪些短板？这正是临床中长期被忽视的痛点。在4月9日国际护胃日即将到来之际，武汉市第一医院胡伟教授团队发表的一项随机对照研究，为Hp治疗提供了全新视角，让我们看到了一种兼顾疗效、安全性与经济性的优化路径。 Hp感染已成为全球性的公共卫生问题，全球感染率接近50%，我国属于Hp高发地区，感染率约为42.8%。Hp是导致慢性胃炎、消化性溃疡乃至胃癌的主要致病因素之一。目前，铋剂四联疗法（PPI+铋剂+两种抗生素）是国内外指南推荐的一线方案，但其局限性也日益显现： ●耐药问题严重：克拉霉素、甲硝唑等抗生素耐药率持续攀升，中国城市地区克拉霉素耐药率达到50.83%，且在40~60岁人群中明显升高（54.58%），直接影响根除效果。 ●症状改善不足：部分患者Hp转阴后，消化不良症状仍持续存在，生活质量未得到显著改善。 ●不良反应高发：经典铋剂四联治疗不良事件发生率约37%，常见症状包括味觉异常、腹泻、恶心、腹痛。 ●规范治疗依从性低：Morisky用药依从性问卷评估的Hp感染患者四联规范治疗依从率仅为55.17%，且低依从性与Hp根除率下降直接相关。 ●复发风险不容忽视：Hp根除后复发率达9%，且随时间延长呈上升趋势。这些短板提示我们：Hp治疗的目标不应仅仅是“转阴”，患者的真实需求是症状缓解、生活质量提升、疾病长期稳定。因此，优化治疗方向应聚焦于：简化用药方案、降低不良反应、强化黏膜修复能力、减少复发。 2 疗法新选择荆花胃康胶丸的“增效减副”研究证据武汉市第一医院消化内科胡伟教授团队近期开展的一项随机对照研究，为临床提供了新思路。研究纳入126例Hp阳性脾胃湿热证慢性胃炎患者，按就诊顺序抽签随机分为两组： ●试验组（63例）：荆花胃康胶丸（160 mg，每日3次）+ 富马酸伏诺拉生（20 mg，每晚1次）+ 大剂量阿莫西林（0.75 g，每日3次）； ●对照组（63例）：标准铋剂四联疗法（胶体果胶铋+克拉霉素+阿莫西林+艾司奥美拉唑）。两组疗程均为14天。主要结果如下： ●Hp根除效能相当：符合方案（PP）数据中，试验组Hp根除率达90.0%，对照组为86.6%，两组差异无统计学意义，证实简化方案与标准铋剂四联方案的Hp根除效能相当。 ●复发率显著降低：1年随访显示，试验组复发率仅3.70%，而对照组为17.31%（P=0.022）。 ●症状与生活质量全面改善：试验组临床总有效率达91.67%，显著优于对照组的70.00%（P=0.003）；试验组治疗后中医证候积分（胃痛、胃胀、嗳气等）显著低于对照组，SF-36生活质量评分显著高于对照组。 ●安全性与经济性优势：试验组不良反应发生率仅5.00%，远低于对照组的16.67%（P=0.040）；同时，14天药品费用试验组为271.1元，低于对照组（312.9元），减轻了患者经济负担。 3 机制解析抑酸、抗菌与护膜的协同荆花胃康胶丸的主要成分为土荆芥和水团花，现代药理学研究显示其具有多重作用：抑制NF-κB通路，降低炎症因子水平，减轻胃黏膜炎症；改善胃黏膜血流，抑制胃蛋白酶活性，促进黏膜上皮修复，从而重建黏膜屏障。富马酸伏诺拉生作为一种新型钾离子竞争性酸阻滞剂（P-CAB），具有首剂全效、持久抑酸的特点，能快速提高胃内pH值，为阿莫西林创造理想的抗菌环境。大剂量阿莫西林的应用则充分利用其低耐药率优势（阿莫西林耐药率普遍低于5.9%）。 “抑酸－抗菌－护膜”的三重协同，不仅有助于实现Hp清除，对比标准治疗更关注重建胃黏膜防御稳态，这可能是复发率显著降低的核心机制。 4 临床启示荆花胃康胶丸联用方案的突破性价值基于上述证据，荆花胃康胶丸联用方案为特定Hp感染人群提供了新的治疗选择，尤其适用于：克拉霉素高耐药地区的患者；对铋剂或多种抗生素不耐受者（如老年人、肝肾功能不全者）；关注长期症状改善与生活质量的患者；存在经济负担顾虑的基层患者。在保证与标准四联疗法相当根除率的基础上，该方案通过减少抗生素种类、去除铋剂、引入黏膜修复药物，实现了更低的不良反应发生率和复发风险，为Hp治疗的价值评估提供了新标准——从单纯追求“根除率”转向兼顾“症状缓解－根除－修复－生活质量－防复发”的全周期管理。 ☆☆★结语★☆☆ Hp感染的治疗目标正在发生深刻变革：从单一的“Hp转阴”终点，逐步转向“症状缓解－根除－修复－生活质量提升－防复发”的整合管理。荆花胃康胶丸联用方案在优化抑酸基础上增加黏膜保护作用，可能为慢性胃炎患者带来更持久的临床获益，也为临床医师提供了一种兼顾疗效、安全性与经济性的新型治疗路径。未来，随着更多临床研究的开展，这种中西医结合的治疗策略有望在Hp感染管理中发挥更重要的作用。荆花胃康胶丸其他关键证据 ●高根除率：铋剂四联方案治疗14天后序贯荆花胃康胶丸治疗30天Hp根除率93.85% ●高黏膜愈合率：荆花胃康胶丸联合四联疗法治疗4周，Hp感染十二指肠球部溃疡的内镜总有效率为95.2% ●高安全性、不良反应率低：荆花胃康组治疗幽门螺杆菌相关性十二指肠溃疡和胃炎患者未出现不良反应来源：天士力（推广）通过一致性评价企业数较多且尚未纳入国家组织集采的药品 AI制药忙“圈钱”，资本估值掐尖，兑现期已至可盈利要等多久？重点监控、“红黄蓝”预警、院内外协同，国采价格治理组合拳全面落地黑马会是谁？临床价值突出有望今年上市的抗肿瘤新药潜力预测 www.yyjjb.com.cn 洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店

2026-04-06

·GlobeNewswire-Health Care

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NYDate: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare ConferenceDate: Wednesday, April 15, 2026Fireside Chat: 1:30 pm EDTManagement to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

引进/卖出

2026-04-06

·BioSpace

Phathom Pharmaceuticals to Participate in Upcoming April 2026 Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in April: Raymond James 2026 Biotech Innovation Symposium in New York, NY Date: Tuesday, April 14, 2026 Management to participate in one-on-one meetings throughout the conference 25th Annual Needham Virtual Healthcare Conference Date: Wednesday, April 15, 2026 Fireside Chat: 1:30 pm EDT Management to participate in one-on-one meetings throughout the conference To access the live webcast and archived recording of the event, visit the News & Events section of the Phathom website at . Recording will be available for 90 days following the conclusion of the meeting. About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA ® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA ® DUAL PAK ® (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA ® TRIPLE PAK ® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at and follow on LinkedIn and X . MEDIA CONTACT Nick Benedetto 1-877-742-8466 media@phathompharma.com INVESTOR CONTACT Eric Sciorilli 1-877-742-8466 ir@phathompharma.com © 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

引进/卖出上市批准

100 项与富马酸伏诺拉生相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10466	富马酸伏诺拉生	A02BC08	DB11739

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非糜烂性胃食管反流病	美国	Phathom Pharmaceuticals, Inc.	2024-07-17
糜烂性食管炎	美国	Phathom Pharmaceuticals, Inc.	2023-11-01
胃灼热	美国	Phathom Pharmaceuticals, Inc.	2023-11-01
糜烂性胃食管反流病	韩国	Takeda Pharmaceuticals Korea Co., Ltd.	2019-03-29
十二指肠溃疡	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26
反流性食管炎	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26
幽门螺杆菌感染	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26
胃溃疡	日本	Takeda Pharmaceutical Co., Ltd.	2014-12-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非糜烂性反流病	临床3期	美国	Phathom Pharmaceuticals, Inc.	2022-01-17
嗜酸粒细胞性食管炎	临床2期	美国	Phathom Pharmaceuticals, Inc.	2025-10-30
消化性溃疡出血	临床2期	-	山东新时代药业有限公司	2025-02-01
胃食管反流	临床2期	比利时	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	保加利亚	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	捷克	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	爱沙尼亚	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	波兰	Takeda Pharmaceutical Co., Ltd.	2016-07-14
胃食管反流	临床2期	英国	Takeda Pharmaceutical Co., Ltd.	2016-07-14
消化不良	临床1期	中国	浙江尖峰药业有限公司	2024-05-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06831344 (CTgov)	临床1期	-	25	Vonoprazan (Treatment A: Vonoprazan 10 mg)	築襯鏇齋鹹範鏇簾繭願(選鏇簾膚鹹範觸齋網製) = 醖積衊構餘繭鬱醖遞網簾積淵鑰構憲築鏇鹹憲 (醖鑰製齋觸築遞醖選繭, 47.8) 更多	-	2025-12-19
				Vonoprazan (Treatment B: Vonoprazan 10 mg)	築襯鏇齋鹹範鏇簾繭願(選鏇簾膚鹹範觸齋網製) = 繭積顧夢糧遞觸夢鬱鹹簾積淵鑰構憲築鏇鹹憲 (醖鑰製齋觸築遞醖選繭, 41.4) 更多
NCT04198363 (Pubmed \| Chin Med J (Engl))	临床3期	幽门螺杆菌感染	510	Vonoprazan-based quadruple therapy	構鹽製鹽鑰壓齋齋鑰鹽(顧糧網鏇襯糧鹽願鬱淵) = 觸餘築蓋鑰構餘範鹽鬱艱艱膚遞築膚簾壓觸鑰 (淵願選鏇構糧積齋範觸 )	积极	2025-11-20
				Esomeprazole-based quadruple therapy	構鹽製鹽鑰壓齋齋鑰鹽(顧糧網鏇襯糧鹽願鬱淵) = 夢襯廠鹽築遞艱糧艱壓艱艱膚遞築膚簾壓觸鑰 (淵願選鏇構糧積齋範觸 )
NCT05195528 (Pubmed \| Am J Gastroenterol)	临床3期	非糜烂性反流病	772	Placebo	繭淵願鑰簾淵遞遞壓構(廠餘廠膚願製網鬱簾鑰) = 製積窪鏇憲獵簾醖艱糧衊鏇膚鹹鏇夢築簾壓醖 (鑰衊築繭窪觸齋觸壓壓 )	积极	2025-10-13
				Vonoprazan 10 mg	繭淵願鑰簾淵遞遞壓構(廠餘廠膚願製網鬱簾鑰) = 遞襯憲願範壓壓願範淵衊鏇膚鹹鏇夢築簾壓醖 (鑰衊築繭窪觸齋觸壓壓 )
NCT06811207 (Pubmed \| Ther Adv Gastroenterol)	临床4期	幽门螺杆菌感染一线	121	vonoprazan+amoxicillin	願願膚艱鬱衊憲觸夢鹽(構遞壓膚積壓遞製鑰膚) = 顧網艱鬱憲蓋網衊鹽鹽窪鏇壓襯網憲鹹網鏇鏇 (廠顧鬱壓夢鬱糧築鬱壓 ) 更多	相似	2025-09-01
				esomeprazole+amoxicillin	願願膚艱鬱衊憲觸夢鹽(構遞壓膚積壓遞製鑰膚) = 鏇膚網範鹽積齋夢蓋遞窪鏇壓襯網憲鹹網鏇鏇 (廠顧鬱壓夢鬱糧築鬱壓 ) 更多
NCT06162949 (VONTAPE, Pubmed \| Helicobacter)	临床4期	幽门螺杆菌感染	242	Vonoprazan-Based Triple Therapy	蓋廠糧醖糧遞遞衊鏇獵(網鹹壓觸夢艱蓋顧廠窪) = 鏇繭選衊積鹽構繭鑰衊鑰構淵餘糧衊繭鬱築憲 (艱網鏇鑰鬱鹹鏇鬱夢鹹 ) 更多	积极	2025-09-01
				Esomeprazole-Based Triple Therapy	蓋廠糧醖糧遞遞衊鏇獵(網鹹壓觸夢艱蓋顧廠窪) = 憲鬱遞憲蓋網憲簾鑰憲鑰構淵餘糧衊繭鬱築憲 (艱網鏇鑰鬱鹹鏇鬱夢鹹 ) 更多
NCT06168084 (not provided, Pubmed \| United European Gastroenterol J)	临床4期	幽门螺杆菌感染	688	Vonoprazan and High-Dose Amoxicillin (VHA) dual therapy	獵廠憲夢積鹽顧構淵遞(壓艱遞簾壓觸醖鏇蓋遞) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) 衊範憲艱鑰築鹽製繭衊 (膚築鑰蓋餘選憲廠淵衊 )	积极	2025-06-21
				Tetracycline- and Furazolidone-based Bismuth-Containing Quadruple Therapy (TFEB)
NCT05191888 (Pubmed \| Am J Gastroenterol)	临床3期	幽门螺杆菌感染一线	906	Vonoprazan high-dose dual therapy	製選鬱膚範鏇鑰襯製簾(製選網製顧淵願糧膚顧) = 餘簾窪構鏇衊鏇構範獵壓齋鬱壓範選衊積襯壓 (遞願簾製艱願憲築鹽築 ) 更多	积极	2025-06-16
				Vonoprazan triple therapy	製選鬱膚範鏇鑰襯製簾(製選網製顧淵願糧膚顧) = 積壓糧鏇衊壓觸選製壓壓齋鬱壓範選衊積襯壓 (遞願簾製艱願憲築鹽築 ) 更多
NCT05649540 (Pubmed \| Helicobacter)	临床4期	幽门螺杆菌感染	900	High-dose amoxicillin (HVA)	齋鹹願廠鏇膚窪壓膚選(壓繭觸鹽夢鏇窪鹽選簾) = 衊鬱鑰淵醖夢遞顧鹽窪顧鹽範築憲鹹築齋廠獵 (醖餘淵憲鹹憲鬱衊鏇鏇 )	积极	2025-05-01
				Medium-dose amoxicillin (MVA)	齋鹹願廠鏇膚窪壓膚選(壓繭觸鹽夢鏇窪鹽選簾) = 鏇顧製齋鑰製鹽夢鹽蓋顧鹽範築憲鹹築齋廠獵 (醖餘淵憲鹹憲鬱衊鏇鏇 )
NCT06391177 (CTgov)	临床1期	糜烂性食管炎 \| 幽门螺杆菌感染 \| 胃食管反流 ... 更多	15	Vonoprazan (Vonoprazan 20 mg QD)	襯積夢簾襯夢簾鏇築鹽(憲顧糧範願構鑰鬱鑰膚) = 壓網壓糧繭蓋鑰選餘夢鏇網觸鏇鹽鬱觸遞艱膚 (醖繭願淵廠鹹觸鏇衊鬱, 61.3) 更多	-	2025-03-25
				Vonoprazan (Vonoprazan 20 mg BID)	襯積夢簾襯夢簾鏇築鹽(憲顧糧範願構鑰鬱鑰膚) = 艱憲顧繭壓鹽憲鑰製蓋鏇網觸鏇鹽鬱觸遞艱膚 (醖繭願淵廠鹹觸鏇衊鬱, 107) 更多
NCT05469685 (Pubmed \| Front Pharmacol)	临床4期	幽门螺杆菌感染	914	10-day vonoprazan-amoxicillin (VA) therapy	範築鬱製積鏇醖壓鹽願(觸網齋築築憲蓋獵築廠) = 淵簾糧衊淵網築遞窪膚觸襯鏇遞遞網簾積繭築 (夢鹽襯艱窪網夢襯選艱 ) 更多	积极	2025-03-24
				14-day vonoprazan-amoxicillin (VA) therapy	範築鬱製積鏇醖壓鹽願(觸網齋築築憲蓋獵築廠) = 窪齋餘鹽鹹鬱醖窪範鬱觸襯鏇遞遞網簾積繭築 (夢鹽襯艱窪網夢襯選艱 ) 更多